Neoadjuvant treatment for esophageal squamous cell carcinoma.
about
Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 YearsA bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database.CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamouClinical features, outcomes and treatment-related pneumonitis in elderly patients with esophageal carcinoma.High GPX1 expression promotes esophageal squamous cell carcinoma invasion, migration, proliferation and cisplatin-resistance but can be reduced by vitamin DActivin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.Case-matched analysis of combined thoracoscopic-laparoscopic versus open esophagectomy for esophageal squamous cell carcinomaOncological and surgical outcomes of minimally invasive versus open esophagectomy for esophageal squamous cell carcinoma: a matched-pair comparative study.miR141 expression is downregulated and negatively correlated with STAT5 expression in esophageal squamous cell carcinoma.SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma.Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer.Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma.Survival benefit of surgery to patients with esophageal squamous cell carcinomaChemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.Monitoring sputum culture in resected esophageal cancer patients with preoperative treatment.Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma.Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.Tumor suppressor miR-128-3p inhibits metastasis and epithelial-mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer.Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro.Overexpression of cannabinoid receptor 1 in esophageal squamous cell carcinoma is correlated with metastasis to lymph nodes and distant organs, and poor prognosis.Elevated Nectin-2 expression is involved in esophageal squamous cell carcinoma by promoting cell migration and invasion.Neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy: is it a superior approach for locally advanced resectable esophageal squamous cell carcinoma?
P2860
Q28081365-C66BA6BD-7ED5-479E-A3FF-4E2C58722FC8Q31061475-381E5014-D3CD-4ADA-BC17-81E496415464Q33850915-C498AEF5-966B-42E6-983F-8B809C6A27C4Q34255601-B024F4D6-579A-41C6-9E6E-407D916761BAQ34414917-069E1D3F-6737-425F-8E2D-7AA40368A1A6Q35803684-3EBD4DCE-A7D0-48AF-8C1C-76FB079D55B9Q36183129-D1987573-06AA-457C-862C-8018F42DD4C2Q36317778-F1EE5F67-3547-4007-810C-8C69D3EC93E5Q36824723-6F805246-74CD-4667-B204-0663D3B715AFQ38722229-070FFE93-14A5-4B07-9669-3B41A13C2233Q38809817-A46D05D0-5918-4DCF-99D8-8D48602DA8FBQ39053426-A60C8B92-BF08-44F6-A610-FE1E5A9F2922Q39201802-8F98E83E-3A89-4328-9458-3CB4364657C5Q39223929-4E055D76-B488-41D9-8F33-8F48D729CB6BQ39899850-4727C84B-769F-43F6-A399-33A5A67148F4Q44807317-71EC2734-9BFC-4034-B7E2-81B8D423324BQ46310733-05D9A756-FBA5-45CC-91B2-5CDD05BA027BQ48271971-C6604975-3969-4062-BAAC-3CA0E7364844Q49492743-27551479-D13A-4C0B-B5C2-9116BFAE9BC2Q50063155-16B1D661-69E2-4543-AE7B-2A9A17B07456Q51033477-7C007394-A141-44CA-A14E-392BE0C9A96BQ51262782-A5E4E29F-096E-4298-B2DD-97E7D9DFCDA9Q52649773-1E8790D6-F931-404D-A8A2-98CA26314D95Q53833338-4C8A7083-1D80-404B-9A36-AD9B0A9E708A
P2860
Neoadjuvant treatment for esophageal squamous cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neoadjuvant treatment for esophageal squamous cell carcinoma.
@en
type
label
Neoadjuvant treatment for esophageal squamous cell carcinoma.
@en
prefLabel
Neoadjuvant treatment for esophageal squamous cell carcinoma.
@en
P2093
P2860
P356
P1476
Neoadjuvant treatment for esophageal squamous cell carcinoma.
@en
P2093
Hideo Baba
Masayuki Watanabe
Naoya Yoshida
Yoshifumi Baba
P2860
P304
P356
10.4251/WJGO.V6.I5.121
P577
2014-05-01T00:00:00Z